{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Other+approved+anti-cancer+agent",
    "query": {
      "intervention": "Other approved anti-cancer agent"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Other+approved+anti-cancer+agent&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T03:18:21.781Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02446431",
      "title": "Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Miller Children's & Women's Hospital Long Beach",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "31 Years",
        "sex": "ALL",
        "summary": "12 Months to 31 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-07",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2015-05-18",
      "last_synced_at": "2026-10-11T03:18:21.781Z",
      "location_count": 2,
      "location_summary": "Long Beach, California • Orange, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02446431"
    },
    {
      "nct_id": "NCT01777776",
      "title": "Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Metastatic BRAF Mutant Melanoma"
      ],
      "interventions": [
        {
          "name": "LEE011",
          "type": "DRUG"
        },
        {
          "name": "LGX818",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Array BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2013-07",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-09-13",
      "last_synced_at": "2026-10-11T03:18:21.781Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Detroit, Michigan • New York, New York + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01777776"
    },
    {
      "nct_id": "NCT03944447",
      "title": "Outcomes Mandate National Integration With Cannabis as Medicine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Pain",
        "Chronic Pain Syndrome",
        "Chronic Pain Due to Injury",
        "Chronic Pain Due to Trauma",
        "Fibromyalgia",
        "Seizures",
        "Hepatitis C",
        "Cancer",
        "Crohn Disease",
        "HIV/AIDS",
        "Multiple Sclerosis",
        "Traumatic Brain Injury",
        "Sickle Cell Disease",
        "Post Traumatic Stress Disorder",
        "Tourette Syndrome",
        "Ulcerative Colitis",
        "Glaucoma",
        "Epilepsy",
        "Inflammatory Bowel Diseases",
        "Parkinson Disease",
        "Amyotrophic Lateral Sclerosis",
        "Chronic Traumatic Encephalopathy",
        "Anxiety",
        "Depression",
        "Insomnia",
        "Autism",
        "Opioid-use Disorder",
        "Bipolar Disorder",
        "Covid19",
        "SARS-CoV Infection",
        "COVID-19",
        "Corona Virus Infection",
        "Coronavirus"
      ],
      "interventions": [
        {
          "name": "Cannabis, Medical",
          "type": "DRUG"
        },
        {
          "name": "RYAH-Medtech Inhaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "OMNI Medical Services, LLC",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 200000,
      "start_date": "2018-12-01",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-02",
      "last_synced_at": "2026-10-11T03:18:21.781Z",
      "location_count": 17,
      "location_summary": "Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03944447"
    },
    {
      "nct_id": "NCT04291079",
      "title": "SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "SRK-181",
          "type": "BIOLOGICAL"
        },
        {
          "name": "anti-PD-(L)1 antibody therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Scholar Rock, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 112,
      "start_date": "2020-04-23",
      "completion_date": "2025-04-14",
      "has_results": false,
      "last_update_posted_date": "2025-04-29",
      "last_synced_at": "2026-10-11T03:18:21.781Z",
      "location_count": 18,
      "location_summary": "Fullerton, California • La Jolla, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04291079"
    },
    {
      "nct_id": "NCT03388632",
      "title": "Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Treatment-Refractory Cancers"
      ],
      "interventions": [
        {
          "name": "rhIL-15",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Tumor biopsies",
          "type": "PROCEDURE"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "ECHO",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT Scan",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 31,
      "start_date": "2018-02-05",
      "completion_date": "2025-05-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-11T03:18:21.781Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03388632"
    },
    {
      "nct_id": "NCT02740985",
      "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Malignancies",
        "Non-Small Cell Lung Cancer (NSCLC)",
        "Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)",
        "Colorectal Carcinoma (CRC)"
      ],
      "interventions": [
        {
          "name": "AZD4635",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Oleclumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 313,
      "start_date": "2016-06-17",
      "completion_date": "2023-03-31",
      "has_results": false,
      "last_update_posted_date": "2023-05-26",
      "last_synced_at": "2026-10-11T03:18:21.781Z",
      "location_count": 17,
      "location_summary": "Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02740985"
    },
    {
      "nct_id": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AML (Acute Myelogenous Leukemia)",
        "Acute Lymphoid Leukemia (ALL)",
        "Acute Leukemia (Category)",
        "MDS (Myelodysplastic Syndrome)",
        "CML (Chronic Myelogenous Leukemia)",
        "CLL (Chronic Lymphocytic Leukemia)",
        "Prolymphocyctic Leukemia",
        "Chronic Myelomonocytic Leukemia (CMML)",
        "Myeloproliferative Neoplasm (MPN)",
        "Lymphoma",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Conditioning Regimen A",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen B",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen C",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen D",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen E",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "PTCy (50 mg/kg D3, D4)",
          "type": "DRUG"
        },
        {
          "name": "PTCy (25 mg/kg D3, D4)",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Growth Factors",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Blood Products",
          "type": "PROCEDURE"
        },
        {
          "name": "Supportive Care: Infection Prophylaxis",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Intravenous immune globulin (IVIG)",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Seizure prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Monitoring and management of CRS",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Prophylaxis against infections",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Prophylaxis against infections",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Lipid elevations",
          "type": "OTHER"
        },
        {
          "name": "Study treatment compliance",
          "type": "OTHER"
        },
        {
          "name": "Prohibited Concomitant Therapy",
          "type": "OTHER"
        },
        {
          "name": "Permitted Concomitant Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 358,
      "start_date": "2025-07-25",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-10-11T03:18:21.781Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06859424"
    },
    {
      "nct_id": "NCT02238496",
      "title": "Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Tumor, Recurrent",
        "Glioblastoma",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligodendroglioma",
        "Mixed Glioma"
      ],
      "interventions": [
        {
          "name": "Cytoreductive surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Perifosine",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Andrew B Lassman, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2014-12-08",
      "completion_date": "2021-02-14",
      "has_results": false,
      "last_update_posted_date": "2023-05-25",
      "last_synced_at": "2026-10-11T03:18:21.781Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02238496"
    },
    {
      "nct_id": "NCT05860296",
      "title": "Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Nonsmall Cell",
        "Lung Cancer Stage IV",
        "Lung Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "SLC-391",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "SignalChem Lifesciences Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2023-05-31",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-11T03:18:21.781Z",
      "location_count": 6,
      "location_summary": "Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05860296"
    },
    {
      "nct_id": "NCT01231594",
      "title": "A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "GSK2118436",
          "type": "DRUG"
        },
        {
          "name": "GSK1120212",
          "type": "DRUG"
        },
        {
          "name": "Other approved anti-cancer agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2010-11-05",
      "completion_date": "2018-04-09",
      "has_results": false,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-10-11T03:18:21.781Z",
      "location_count": 25,
      "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 19 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231594"
    }
  ]
}